Phaxiam Therapeutics Sa (PHXM)

founded in 2004, erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. its first product, working by starving tumors, has completed its phase iii development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. the company has a production unit located in lyon with “pharmaceutical establishment” status. it has signed two distribution partnership agreements, with orphan europe-recordati (in europe) and teva (in israel).